secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-101620
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne MD
----------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation to DYNE-251 for DMD amenable to exon 51 skipping.
- Designation based on DELIVER trial data showing sustained functional improvement over 18 months.
- DYNE-251 now joins DYNE-101 (DM1) as Dyne's second compound to receive this designation.
- Registrational expansion cohort data expected late 2025; BLA submission for accelerated approval anticipated early 2026.
- Benefits include rolling review, Priority Review eligibility, and enhanced FDA support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025101620/0000950170-25-101620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017025101620/dyn-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer